TY - JOUR
T1 - Nonisotopic single strand conformation analysis of the 5α-reductase type 2 gene for the diagnosis of 5α-reductase deficiency
AU - Hiort, Olaf
AU - Sinnecker, Gernot H.G.
AU - Willenbring, Holger
AU - Lehners, Andrea
AU - Zöllner, Anke
AU - Struve, Dagmar
N1 - Copyright:
Copyright 2007 Elsevier B.V., All rights reserved.
PY - 1996
Y1 - 1996
N2 - 5α-Reductase deficiency is a rare autosomal recessive disorder of defective virilization in karyotypic males due to reduced conversion of testosterone to dihydrotestosterone. The gene encoding the affected 5α- reductase type 2 enzyme has recently been cloned, and mutations within the coding region have been discovered as the cause of this disease. We address the possibility of a rapid nonradioactive molecular genetic screening technique for initial diagnosis and report different point mutations in this gene in eight unrelated patients with clinical features of 5α-reductase deficiency. For molecular genetic analysis, DNA from peripheral blood leukocytes was studied. The coding region of the 5α-reductase type 2 gene was characterized by exon-specific PCR amplification, nonradioactive single strand conformation analysis, and direct sequencing. In seven patients, homozygous point mutations were identified (Leu55-Gln, ΔMet157, Gly196-Ser, Arg227-Gln, Ala228-Thr, and His23-Arg). One individual was a compound heterozygote carrier of two mutations (Ile112-Asn and Gln126-Arg). We conclude that molecular genetic characterization of point mutations in the 5α-reductase type 2 gene may be used as an additional valuable procedure for the diagnosis of this disorder.
AB - 5α-Reductase deficiency is a rare autosomal recessive disorder of defective virilization in karyotypic males due to reduced conversion of testosterone to dihydrotestosterone. The gene encoding the affected 5α- reductase type 2 enzyme has recently been cloned, and mutations within the coding region have been discovered as the cause of this disease. We address the possibility of a rapid nonradioactive molecular genetic screening technique for initial diagnosis and report different point mutations in this gene in eight unrelated patients with clinical features of 5α-reductase deficiency. For molecular genetic analysis, DNA from peripheral blood leukocytes was studied. The coding region of the 5α-reductase type 2 gene was characterized by exon-specific PCR amplification, nonradioactive single strand conformation analysis, and direct sequencing. In seven patients, homozygous point mutations were identified (Leu55-Gln, ΔMet157, Gly196-Ser, Arg227-Gln, Ala228-Thr, and His23-Arg). One individual was a compound heterozygote carrier of two mutations (Ile112-Asn and Gln126-Arg). We conclude that molecular genetic characterization of point mutations in the 5α-reductase type 2 gene may be used as an additional valuable procedure for the diagnosis of this disorder.
UR - http://www.scopus.com/inward/record.url?scp=0029835366&partnerID=8YFLogxK
U2 - 10.1210/jc.81.9.3415
DO - 10.1210/jc.81.9.3415
M3 - Journal articles
C2 - 8784107
AN - SCOPUS:0029835366
SN - 0021-972X
VL - 81
SP - 3415
EP - 3418
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
IS - 9
ER -